Geron Corp (GERN) option IV into FDA Oncologic Drugs Advisory Committee meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
- Hertz cuts guidance, announces notes and stock offerings, shares sink
Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs
March 15, 2024 3:51 AM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Geron Corporation (NASDAQ: GERN) to $5.00 (from $4.00) while maintaining a Buy rating.
The analyst comments "
We expect GERN to trade higher tomorrow (+85-90% in after hours trading) following the FDA's Advisory... More
